| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7300669 | FOUGERA PHARMS | Fluticasone lotion having improved vasoconstrictor activity |
Oct, 2019
(4 years ago) | |
Cutivate is owned by Fougera Pharms.
Cutivate contains Fluticasone Propionate.
Cutivate has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Cutivate are:
- US7300669
Cutivate was authorised for market use on 31 March, 2005.
Cutivate is available in lotion;topical dosage forms.
Cutivate can be used as relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients one year of age or older.
The generics of Cutivate are possible to be released after 20 October, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 16, 2018 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 31 March, 2005
Treatment: Relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients one year of age or older
Dosage: LOTION;TOPICAL
CUTIVATE family patents
